MetaStat Inc is primarily active in the biotechnology industry.

The main competitors of MetaStat Inc in the market are companies like Biocept Inc, QIAGEN N.V., Veracyte Inc, and Genomic Health Inc.

MetaStat Inc is a leading company in the field of metastatic cancer research and diagnostics. With a rich history and strong background in cancer biology, MetaStat Inc has been dedicated to developing innovative solutions for the detection and treatment of metastatic cancer. Founded in [insert founding year], the company has made significant advancements in understanding the molecular mechanisms behind cancer metastasis. MetaStat Inc's cutting-edge technologies and expertise in the field have positioned it as a trusted partner for both patients and healthcare professionals. Their commitment to improving patient outcomes through groundbreaking research and diagnostic tools is remarkable.

MetaStat Inc has achieved several significant milestones. The company has successfully developed and commercialized novel diagnostic tests that provide critical information for managing cancer patients. MetaStat Inc has also collaborated with prestigious academic institutions and leading cancer centers to validate its products and technology. Additionally, the company has secured strategic partnerships and licensing agreements, further enhancing its market presence. MetaStat Inc continues to advance its research and development efforts, aiming to revolutionize the diagnosis and treatment of cancer by providing actionable insights to healthcare professionals.

MetaStat Inc is primarily present in the United States, focusing mainly on the domestic market. However, it also operates in select regions internationally.

MetaStat Inc represents values of innovation, integrity, and collaboration in its corporate philosophy. With a commitment to transforming the way cancer is diagnosed and treated, MetaStat Inc focuses on developing novel diagnostic tools and therapeutic approaches. By leveraging its unique understanding of the metastatic process, the company aims to provide personalized solutions for patients and improve clinical outcomes. Through continuous research and development, MetaStat Inc strives to deliver cutting-edge technologies and solutions that address unmet medical needs. With a patient-centric approach, the company aims to bring advancements in cancer care and make a positive impact in the lives of those affected by this disease.

Converted at the current exchange rate, the MetaStat share trades at 0,00 EUR (0,00 USD).

MetaStat Inc is a biotechnology company that offers innovative solutions for the treatment of cancer. The company utilizes advanced technologies to study cancer metastasis and promote the development of effective therapies. The three main business areas of MetaStat are diagnostics, therapeutics, and research services. In the diagnostics field, the company provides test kits that enable doctors to detect cancer metastasis early and optimize treatment options. These tests can be used for both diagnostic purposes and monitoring the progression of the disease. Therapeutically, MetaStat offers a range of treatment options for cancer. For example, the company has developed a novel cancer drug called MenaCalc, which inhibits the metastasis of cancer cells. MenaCalc is based on the discovery that Mena, a human protein product, plays a key role in the formation of cancer metastasis. The drug has already been tested in clinical studies and shows promising results for the treatment of breast, ovarian, and lung cancer. The research services area includes supporting academic institutions and pharmaceutical companies in the development of cancer drugs. MetaStat offers a deep understanding of the mechanisms of cancer metastasis and can provide value to customers in exploring various treatment options for cancer through its comprehensive knowledge in this field. Another important advantage of MetaStat is its partnership with the MD Anderson Cancer Center. This collaboration allows the company to leverage the expertise of the renowned cancer research center and translate research findings into practical applications. The future growth prospects for MetaStat are promising. The market for cancer therapeutics, diagnostics, and research services is enormous, and MetaStat is well-positioned to benefit from this growth. The company has already built strong relationships with academic institutions and pharmaceutical companies and has extensive expertise in the field of cancer metastasis. Furthermore, with the introduction of MenaCalc into clinical trials, MetaStat has developed a potentially groundbreaking drug that could revolutionize cancer therapies. With an increasing number of cancer patients worldwide, there is a great need for effective treatment options, and MetaStat is ready to meet that need. In summary, MetaStat Inc is an innovative company focused on the research and treatment of cancer. With its three main business areas of diagnostics, therapeutics, and research services, the company will cover every aspect of cancer research and treatment. With the introduction of MenaCalc into clinical trials and collaboration with one of the world's leading cancer research centers, MetaStat is well-positioned to succeed in the market for cancer diagnostics and treatment.

Pendapatan tidak dapat dihitung untuk MetaStat saat ini.

Laba tidak dapat dihitung untuk MetaStat saat ini.

PER tidak dapat dihitung untuk MetaStat saat ini.

PSR tidak dapat dihitung untuk MetaStat saat ini.

Skor Kualitas AlleAktien untuk MetaStat adalah 4/10.

ISIN dari MetaStat adalah US59140A2033. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari MetaStat adalah A14120. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari MetaStat adalah MTST. Simbol ticker digunakan untuk memperdagangkan saham MetaStat di bursa saham.

MetaStat membayar dividen setiap tahun dalam 0 tahun terakhir.

MetaStat dikelompokkan dalam sektor 'Kesehatan'.

Dividen dari MetaStat dibayarkan dalam USD.